Potential Div Play as Calls Trade in XRX

XRX

Shares of Xerox (XRX) are up .05 to 13.25 today.? XRX is near the top of the 52 week range.

Yesterday paper traded 11k XRX Jan 5 calls for 8.30 and 8.35 and 25300 XRX Jan 7 calls for 6.30 and 6.35.?

  • The ADV is 3907 contracts.?
  • The OI is 2516 and 7793.

An Oddities listener wrote in:

Hi Mark et al…

XRX JAN15 7[25K] and 5[11K] strike calls on PHLX.

Ratio?

Love the show just wish I had the time to listen “live”.

Brian

Volume went up in many round lots.? The trade here was a dividend capture that appeared to work.? The OI today has some open interest so the MM captured some of that volume.? The div play traded on the Oct 11 too.

  • 30-day implied volatility is 22%.? ?
  • 10-day implied volatility is 23%.?
  • 30 day implied volatility is trading below the 10 realized volatility.

Xerox Corporation provides services and technology to enable its customers from small businesses to large global enterprises to focus on their core business. The Company is a diversified business process outsourcing company managing transaction-intensive processes.

Puts trading in MAN- continuing put buyer in here

MAN

Shares of ManpowerGroup (MAN) are up .01 to 72.03.? MAN is at the low end of the 52 week range.

Today paper traded 703 MAN Nov 70 puts for 2.35.?

  • The ADV is 471 contracts.?
  • The OI is 1768.

Volume went up in one block.? This trade was the last in a line of volume paying 2.30 with the final block completing the order for 2.35.? There was buying the day before as well on this strike for 2.15.? Without stock going up the put trader is looking for more weakness.

  • 30-day implied volatility is 26%.? ?
  • 10-day implied volatility is 16%.?
  • 30 day implied volatility is trading above the 10 realized volatility

ManpowerGroup Inc., formerly Manpower Inc. provides workforce solutions and services. The Company provides a comprehensive suite of high-impact workforce solutions and services for the entire business cycle, which includes recruitment and assessment, training and development, career management, outsourcing and workforce consulting.

Puts trade in JNS- looks like put traders are fading the news

JNS

Shares of Janus Capital Group Inc. (JNS) are up 3.49 to 14.60 today.? JNS is making a 52 week high.

Today paper traded 1900 JNS Oct 14 puts for .60.?

  • The ADV is 4380 contracts.?
  • The OI is 0 on the puts.

Volume went up in one large block.? The puts through the offer at the time that are still .60 bid as of this writing.? There is a large jump in IV and paper is mostly buying puts for the now.? IV is up 18 points today in the Oct cycle.

  • 30-day implied volatility is 55%.? ?
  • 10-day implied volatility is 29%.?
  • 30 day implied volatility is trading above the 10 realized volatility

Janus Capital Group Inc., and its subsidiaries (JCG) provide investment management, administration, distribution and related services to financial advisors, individuals and institutional clients through mutual funds, other pooled investment vehicles, separate accounts and sub advised relationships (collectively referred to as investment products) in both domestic and international markets.

Calls roll in ACHN- looks like a roll up

ACHN

Shares of Achillion Pharmaceuticals. Inc. (ACHN) are up .17 to 11.09 today.? ACHN is near the upper end of the 52 week range.

Today paper traded 5000 ACHN Oct 14 calls for .40, and 5000/8000 ACHN Nov 10/12 call spreads for .65.?

  • The ADV is 6538 contracts.?
  • The OI is 9097 in Oct and 9763/4087 on the Nov 10/12.

Volume went up in 3 large blocks.? The Oct 14s are looking like a close with a roll up for more volume on the Nov 10/12.? The trade was probably a diagonal calls spread that worked well and is now rolling up.

  • 30-day implied volatility is 114%.? ?
  • 10-day implied volatility is 70%.?
  • 30 day implied volatility is trading above the 10 realized volatility

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections..